Monoclonal antibody therapy for COVID-19 during pregnancy
Aim. Pregnancy worsens COVID-19 and has been listed by the US Food and Drug Administration as a high risk factor for complicating COVID-19. The severe course of a new coronavirus infection in some pregnant patients has created the prerequisites for the search for treatment methods that can reduce th...
Saved in:
Main Authors: | Diana I. Abdulganieva (Author), Ekaterina V. Dyakova (Author), Era V. Ivanova (Author), Nailya G. Shamsutdinova (Author), Asiya R. Yangurazova (Author), Nigina A. Nigmatullina (Author), Ildar F. Fatkullin (Author) |
---|---|
Format: | Book |
Published: |
ZAO "Consilium Medicum",
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tolerability and outcomes of monoclonal antibody therapy for COVID-19 during pregnancy
by: Claudio V. Schenone, MD, et al.
Published: (2023) -
Monoclonal Antibody-Directed Therapy
Published: (2022) -
Monoclonal Antibody Therapy in Alzheimer's Disease
by: Monica Neațu, et al.
Published: (2023) -
Monoclonal Antibodies
Published: (2021) -
Monoclonal Antibodies
by: Christian Klein (Ed.)
Published: (2018)